Renal angiomyolipomas (AML) contain an admixture of clonal tumour cells with features of several different mesenchymal lineages, implying the existence of an unidentified AML neoplastic stem cell. Biallelic inactivation of TSC2 or TSC1 is believed to represent the driving event in these tumours. Here we show that TSC2 knockdown transforms senescenceresistant cultured mouse and human renal epithelial cells into neoplastic stem cells that serially propagate renal AML-like tumours in mice. mTOR inhibitory therapy of mouse AML allografts mimics the clinical responses of human renal AMLs. Deletion of Tsc1 in mouse renal epithelia causes differentiation in vivo into cells expressing characteristic AML markers. Human renal AML and a renal AML cell line express proximal tubule markers. We describe the first mouse models of renal AML and provide evidence that these mesenchymal tumours originate from renal proximal tubule epithelial cells, uncovering an unexpected pathological differentiation plasticity of the proximal tubule.
R enal angiomyolipomas (AML) are benign, but lifethreatening neoplasms that contain variable admixtures of tumour cells that are histologically and molecularly similar to vascular (angio-), smooth muscle (myo-) and fat (lipo-) lineages 1 . Genetic analyses have shown that these different cell types within an individual AML are clonal 2, 3 , indicating that they must be derived from a common tumour-initiating cell that has the capacity to differentiate into these different lineages, suggestive of a putative neoplastic stem cell. However, the identities and characteristics of the normal cell of origin of AML and of the presumptive AML stem cell remain unknown. Renal AML cells also express molecular markers of the melanocyte lineage 4, 5 , which serve as clinical diagnostic markers. As embryonic neural crest stem cells or neural crest-derived progenitor cells from the adult skin can differentiate to form melanocytes, adipocytes and smooth muscle cells [6] [7] [8] , the cell type of origin of renal AML has been proposed to be an unidentified kidney-resident, neural crestderived lineage 5 . Others have suggested that myoblasts 9 , pericytes 10 or lymphatic endothelium 11 represent the AML cell of origin. It is also possible that another renal cell type could become transformed and reprogrammed to form a neoplastic AML stem cell. In this context is noteworthy that a rare variant of AML, called AMLEC (AML with epithelial cysts) contains epithelial tubular or cystic structures 12 . While it has not yet been conclusively proven, there is some evidence that these epithelial structures may be tumour-derived 13, 14 , implying that the putative AML or AMLEC neoplastic stem cell may also have the capacity to differentiate into renal epithelial cells in some cases.
Multiple and bilateral renal AMLs develop in up to 80% of patients with the autosomal dominant tuberous sclerosis complex (TSC) syndrome (also known as Bourneville-Pringle disease), affecting~1 in 6,000 newborns 4 . AMLs represent the most common cause of mortality in adult TSC patients due to spontaneous haemorrhage of abnormal tumour vasculature and can also cause significant morbidity by compressing adjacent normal kidney tissue, thereby impairing kidney function. TSC patients inherit a loss of function mutation in one allele of either of the TSC1 or TSC2 genes and AMLs in these patients almost always display somatic mutation of the wild type allele [15] [16] [17] . Roughly 80% of all renal AMLs arise sporadically in the general population, affecting~0.6% of females and 0.3% of males 18 . These tumours also almost invariably display biallelic loss of TSC2 or more rarely of TSC1 [15] [16] [17] 19 . The TSC1 (also known as HAMARTIN) and TSC2 (also known as TUBERIN) proteins form a complex that negatively regulates the mTORC1 protein kinase complex, a key node in cellular signalling networks that control cellular growth and proliferation. Consistent with the oncogenic role of constitutive mTORC1 activation, everolimus, an inhibitor of mTORC1, causes regression of renal AMLs in many patients 20 and this therapy isapproved by the U.S. Food and Drug Administration and the European Medicines Agency for the treatment of TSC-associated renal AML. Despite the clear role of TSC1 and TSC2 mutation in the human disease, renal AMLs surprisingly did not develop in numerous mouse models involving homozygous or heterozygous deletion of Tsc1 or Tsc2 (reviewed in ref. 21 ). However, inducible, ubiquitous Cre-mediated deletion of Tsc1 caused the development of small kidney lesions displaying several characteristic renal AML markers such as HMB45, Smooth Muscle Actin (SMA), CATHEPSIN K and VIMENTIN 22 , suggesting that these lesions might represent renal AML precursor lesions. The cell type that gave rise to these lesions was not determined.
In this study we utilised a reverse tumour-engineering approach in mouse and human cells to explore the cell of origin of renal AML. Surprisingly we identified that our renal AML tumour models derive from renal epithelial cells. We further showed that some cells in human renal AMLs, as well as a renal AML cell line, exhibit molecular features of renal proximal tubular epithelial cells. These findings argue that renal AMLs might derive from proximal tubule epithelial cells.
Results
Tsc2 and Cdkn2a loss converts renal cells into AML-forming cells. As renal AMLs are relatively genetically simple tumours that are characterised almost exclusively by recurrent TSC2 or TSC1 mutations 19 , we reasoned that it might be possible to reverse engineer renal AML starting from normal primary cells. We first utilised primary mouse embryo fibroblasts (MEFs) to establish RNAi tools to knockdown Tsc1 and Tsc2. Infection with lentiviruses expressing shRNA-Tsc1 or shRNA-Tsc2 efficiently reduced TSC1 or TSC2 protein abundance, increased phosphorylation of ribosomal protein S6 (Ser240/244) and 4E-BP1 (Thr37/ 46), indicative of mTORC1 activation, and caused accumulation of HIF-1α and the HIF-1α inducible protein GLUT1 (Supplementary Fig. 1a) , mimicking previously published effects of knockout of Tsc1 or Tsc2 in MEFs [23] [24] [25] . Tsc1 or Tsc2 knockdown also inhibited cellular proliferation and induced premature senescence ( Supplementary Fig. 1b, c) , another known consequence of loss of function of TSC1 or TSC2 24, 25 .
As the cell type of origin of renal AML is unknown, we prepared primary cultures from collagenase-digested whole mouse kidneys with the aim of simultaneously isolating different types of kidney cells and cultured them in renal epithelial cell medium. These cultures predominantly comprised E-CADHERIN-expressing epithelial cells with rare VIMENTINexpressing cells ( Supplementary Fig. 2a, b) . Knockdown of Tsc1 or Tsc2 in these cultures also caused rapid loss of proliferative capacity (data not shown). Knockdown of TSC2 in primary human renal proximal tubular epithelial cells similarly caused inhibition of proliferation and the flattened, spread cellular morphology that is characteristic of cellular senescence (data not shown). This loss of proliferative capacity, a common consequence of expression of oncogenes or loss of tumour suppressor genes in primary cell culture systems, represents a limitation to an ex vivo tumour engineering approach.
To overcome this problem we identified that Cdkn2a knockout in MEFs rescued senescence and induced cellular transformation upon knockdown of Tsc1 or Tsc2 ( Supplementary Fig. 1d-i ). Using this information we first observed that while cultures from wild type kidneys lost epithelial appearance upon passaging, cultures from Cdkn2a fl/fl mice infected with a Cre-expressing adenoviral vector to delete Cdkn2a (hereafter designated Cdkn2a Δ/Δ cells) maintained epithelial appearance, proliferated in culture (Fig. 1a) and formed colonies when plated at low density on plastic but did not form colonies in soft agar ( Fig. 1a and Supplementary Fig. 2d ). Infection of cultured Cdkn2a Δ/Δ renal cells with lentiviruses expressing shRNA-Tsc1 or shRNATsc2 increased the rate of proliferation (Fig. 1a) and allowed the formation of colonies in soft-agar ( Fig. 1a and Supplementary  Fig. 2d ), indicative of cellular transformation. Similarly, infection of cultured renal cells from wild type mice with a lentiviral vector expressing both shRNA-Tsc2 and shRNA-Cdkn2a (shRNA-Tsc2 + Cdkn2a) ( Supplementary Fig. 2c ) increased proliferation rate compared with shRNA-Cdkn2a knockdown and allowed growth in soft agar ( Fig. 1b and Supplementary Fig. 2e ). Tsc2 knockdown or Cdkn2a knockdown or knockout alone did not cause cellular transformation (Fig. 1a, b) , demonstrating the cooperativity of this genetic effect. Genotypes that grew in soft agar acquired the stem cell-like characteristic of growth as non-adherent spheres that could be serially passaged (Fig. 1c) . Approximately 9% of cells from the total virus-infected cellular populations formed spheres. Importantly, when injected subcutaneously into female SCID-beige mice, shRNA-Tsc2/Cdkn2a Δ/Δ (n = 12 injections) and shRNA-Tsc2 + Cdkn2a (n = 16 injections) sphere-selected cells formed slowly growing tumours within 1-2 months (Fig. 1d) .
Tumours did not grow in male mice, potentially consistent with the increased incidence of human renal AMLs in females compared to males 18 . Allograft tumours showed several histological similarities to human renal AML and comprised a mixture shRNA-Tsc2
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shRNA-Tsc2 +Cdkn2a a c e d f Fig. 1 An ex vivo genetically engineered model of renal AML. a Proliferation assay, western blot and soft-agar assay of Cdkn2a Δ/Δ primary kidney cells following infection with lentiviruses expressing an empty shRNA (shRNA-Ctrl) or shRNAs against Tsc1 (shRNA-Tsc1) or Tsc2 (shRNA-Tsc2). b Proliferation assay, western blot and soft-agar assay of primary kidney cells infected with lentiviruses expressing shRNAs against Cdkn2a (shRNA-Cdkn2a) or Tsc2 and Cdkn2a (shRNA-Tsc2 + Cdkn2a). All graphs depict mean ± s.d. Student's t test, n = 3. * P < 0.05, * * P < 0.01, * * * P < 0.001. c Phase contrast images of spheres formed in suspension culture conditions from shRNA-Tsc2/Cdkn2a Δ/Δ and shRNA-Tsc2 + Cdkn2a primary kidney cells. of mature adipose tissue, scattered blood vessels and spindle shaped cells (Fig. 1e ). Many tumours additionally exhibited some epithelial tubular or cystic structures (Fig. 1e ), although these made up only a very small component of the entire tumour. At the ultrastructural level, allograft tumours exhibited an expanded endoplasmic reticulum ( Supplementary Fig. 3a-d ) that is reminiscent of the expanded endoplasmic reticulum seen in human renal AML tumours 26 . Importantly, regions of adipocyte differentiation and spindle cells were immunoreactive for an antibody cocktail that recognises the melanocyte markers HMB45 and MART-1, for the melanocyte protein PMEL (the HMB45 antigen), SMA and VIMENTIN (Fig. 1f) , reproducing the molecular characteristics that serve as diagnostic criteria for human renal AML. Approximately 15% of cells in our allograft tumours exhibited immunoreactivity for PMEL ( Supplementary  Fig. 3e ). While the majority of cells in human renal AMLs typically stain strongly and diffusely for CATHEPSIN K 27 , our allograft tumours exhibited a weak diffuse cytoplasmic positivity with~10% of cells exhibiting strong immunoreactivity for CATHEPSIN K (Fig. 1f) . mRNA analysis demonstrated high levels of expression of the melanocyte genes Pmel, Tyrp1, Ctsk (encoding CATHEPSIN K) and Mlana (also known as Mart1, encoding the MART-1 antigen) in allografts compared to normal kidney ( Supplementary Fig. 3g ) and western blotting confirmed that allograft tumours expressed both PMEL and CATHEPSIN K ( Supplementary Fig. 3h, i) . Similarly to human renal AMLs, Fig. 2 Cells from Tsc2/Cdkn2adeficient spheres exhibit stem cell-like characteristics. a shRNA-Tsc2/Cdkn2a Δ/Δ spheres were cultured in specific epithelial-, adipocyte-and neural crest-differentiation media and stained immunofluorescently using antibodies against E-CADHERIN, PMEL (HMB45), SMA or GFAP or stained with Nile Red. Scale bars: 50 μm. b mRNA expression analysis of the indicated genes in sphere cells differentiated using the indicated conditions compared to undifferentiated spheres and normalised to expression levels in freshly isolated primary kidney cells. Graph depicts mean ± s.d. Student's t test, n = 3. * P < 0.05, * * P < 0.01. c Experimental overview of the generation of clonal cell lines (Sphere Clone 1-6 (SC1-6)). d Two independent sphere clones (SC2 and SC4) were cultured in specific adipocyte-and neural crest-differentiation media and stained immunofluorescently using antibodies against PMEL (HMB45), GFAP or SMA or stained with Oil-Red-O. Scale bars: 50 μm.Analyses of two additional sphere clones (SC3 and SC6) are shown in Supplementary Fig. 7a . e Representative pictures of AML-like allograft tumours obtained from SC2 and SC4. Positive immunohistochemical stainings of PMEL(HMB45), SMA, PDGFRβ, E-CADHERIN and CATHEPSIN K. Scale bars: 50 μm. Analyses of tumours from two additional sphere clones are shown in Supplementary Fig. 7c the allograft tumour cells were negative for the endothelial cell marker CD31, which instead labelled scattered dysmorphic blood vessels in the tumours (Fig. 1f) . Human renal AMLs have been shown to harbour numerous cells that express PDGFRβ 10 and allograft tumours exhibited a similar staining pattern (Fig. 1f) . Human renal AMLs stain positively for the neural stem cell marker NG2 28 and our allograft tumours similarly exhibited diffuse NG2 immunoreactivty ( Supplementary Fig. 4a ). While mature normal adipocytes stain positively for S100, adipocytes in human renal AMLs typically do not express S100, but other nonadipocyte components of the tumour have been reported to stain positively in about 28% of renal AML cases 29 . Consistent with this, in our allograft tumours, adipocytes stained negatively for S100 and spindle shaped cells stained positively (Fig. 1f) . In summary, these ex vivo genetically engineered cells derived from a kidney-resident cell type represent an allograft model that shares many histological and molecular features with human renal AML or AMLEC. We next sought to determine whether the AML-like tumour and cellular phenotypes observed in our system are specifically related to the Tsc2 and Cdkn2a loss-of-function genotype or whether any genetic combination that causes transformation and sphere formation would give similar results. In the context of another research project that will be described in detail elsewhere, we discovered that the overexpression of the Myc oncogene in Adeno-Cre-treated renal cell cultures derived from Trp53 fl/fl mice (Myc/Trp53 Δ/Δ ) causes the formation of spheres and these cells form tumours in allograft assays ( Supplementary Fig. 4c-f) . In contrast to the Tsc2/Cdkn2a AML-like tumours, Myc/Trp53 Δ/Δ allograft tumours grew as solid masses of epithelial-like cells, sometimes organised in a pseudo-acinar pattern. Tumour cells typically had low cytoplasmic volumes with enlarged prominent nuclei. No histological similarities with renal AML were evident and tumours showed no immunoreactivity for PMEL (Supplementary Fig. 3e , f), S100 or NG2 ( Supplementary Fig. 4a , b). These findings further support the specificity of the effect of Tsc2 loss-of-function in our engineered renal AML model system.
AML-forming cells have neoplastic stem cell properties.
Given that AML-like tumours derived from our engineered cells comprise multiple different types of cells, as well as the previous proposal that AMLs arise from a neural crest-derived cell type 5 , we cultured shRNA-Tsc2/Cdkn2a Δ/Δ sphere cells in specific adipocyte-, osteoblast-, neural crest-and epithelial-differentiation media to assess their capacity to form different cellular lineages in culture. Cells from spheres could be differentiated into cells that expressed markers of adipocytes (Nile Red and Oil-red-O staining), glia (GFAP), neurons (TUBULIN-β3), melanocytes (HMB45/MART-1), smooth muscle cells (SMA) and epithelial cells (E-CADHERIN) (Fig. 2a) . The observation of a melanocytelike phenotype was supported by the fact that shRNA-Tsc2 + Cdkn2a sphere cells that were differentiated in neural-crest differentiation medium showed similar positive staining for CATHEPSIN K, PMEL, MITF and MART-1 to the B16F1 melanoma cell line ( Supplementary Fig. 5 ). Our findings based on stainings were supported by mRNA expression analyses (Fig. 2b) showing that adipocyte differentiation medium induced expression of the adipocyte-specific gene Lpl, osteoblast differentiation medium induced expression of the osteoblast-specific genes Sp7 and Bglap and neural crest differentiation medium induced the expression of the glial-specific gene Gfap and neuron-specific gene Tubb3. Undifferentiated spheres exhibit high levels of expression of epithelial-specific genes (see later results) including Kap and Vil1, which remained elevated when cultured in epithelial differentiation medium but were greatly reduced when cultured in the other differentiation media. To further demonstrate the specificity of this phenotype we differentiated shRNATsc2 + Cdkn2a spheres in parallel with cultures of shRNACdkn2a kidney cells (which do not form spheres) and cultures from Myc/Trp53 Δ/Δ sphere cells. Only the shRNA-Tsc2 + Cdkn2a spheres but not the two negative control cell lines could be differentiated into Nile Red or PMEL positive cells ( Supplementary  Fig. 6a ) nor did the differentiated cultures upregulate any of the adipocyte, osteoblast or neural-crest lineage specific genes that are induced upon differentiation of shRNA-Tsc2 + Cdkn2a spheres ( Supplementary Fig. 6b ). The two negative control cell lines also showed no expression of PMEL by western blotting (Supplementary Fig. 6c ).
To determine whether single cells within spheres have the stem cell characteristic of being able to differentiate into these multiple cellular lineages we disrupted cells from individual shRNA-Tsc2/ Cdkn2a Δ/Δ spheres and plated them as single cells. These single cells generated new spheres within 10 days and these were passaged to form clonal cell lines (termed SC1-SC6) (Fig. 2c) . Four of six independent single cell-derived clonal lines derived from three independent starting spheres possessed the ability to differentiate into osteoblasts, adipocytes, glia and melanocytes in culture, assessed using stainings ( Fig. 2d and Supplementary  Fig. 7a ) and mRNA expression ( Supplementary Fig. 7b ). These four clones also formed characteristic AML tumours in in vivo allograft assays (six tumours from six injections of each clone) ( Fig. 3f ). Allograft tumours from SC2 and SC4 express melanocyte genes ( Supplementary Fig. 3g ) and the proteins PMEL, MiTF and CATHEPSIN K ( Supplementary Fig. 7d ). These results demonstrate that single cells from our reverse-engineered sphere cell populations have properties of tumour-forming AML stem cells that have the ability to differentiate into several neural crestderived and mesenchymal cellular lineages, as well as into epithelial cells. Interestingly, two of the six clones (SC1, SC5) did not form tumours in allograft experiments (zero tumours from six injections of each clone). These cells could be differentiated into Nile Red-positive and SMA-positive cells in appropriate media, but could not be differentiated into PMEL-or GFAPexpressing cells ( Supplementary Fig. 7e ), demonstrating that not all cells within a sphere have the properties of AML neoplastic stem cells, potentially implying the existence of a hierarchy of differentiation.
Given this mesenchymal differentiation phenotype we next analysed markers of mesenchymal stem cells in our engineered sphere cells. Flow cytometric comparisons of sphere-selected shRNA-Tsc2/Cdkn2a Δ/Δ cells and control Cdkn2a Δ/Δ kidney cells ( Supplementary Fig. 8a ) revealed that both genotypes of sphere cells expressed SCA-1 and CD29, and shRNA-Tsc2/ Cdkn2a Δ/Δ cells specifically expressed the general mesenchymal marker CD73, but none of the cells expressed other characteristic markers of mesenchymal stem cells (CD105, CD106). These findings argue against the idea that we have simply isolated a normal population of kidney-resident mesenchymal stem cells that represent the AML-forming sphere cells in our culture system. The absence of expression of Nanog, Sox2 and Oct4, which are abundantly expressed in ES cells ( Supplementary Fig. 8b ), also argues against an induced pluripotent stem cell phenotype of our engineered sphere cells.
Neoplastic AML stem cells derive from renal epithelial cells. To gain further insight into molecular features of the engineered AML-initiating cells we used RNA sequencing to compare gene expression between primary renal cell cultures 5 days after infection with control or shRNA-Tsc2 + Cdkn2a viruses and spheres derived from shRNA-Tsc2 + Cdkn2a-infected cells harvested 12 days after infection (Fig. 3a) . Gene expression values are provided in Supplementary Data 1. Compared with control infected cells, total populations of shRNA-Tsc2 + Cdkn2a cells displayed 154 genes that were upregulated >8-fold. Gene set enrichment analyses (GSEA) revealed association with expression signatures related to cellular proliferation and mTOR signalling (Supplementary Data 2), consistent with the introduced knockdowns and elevated proliferation rate of these cultures. Comparison of shRNA-Tsc2 + Cdkn2a spheres to shRNA-Tsc2 + Cdkn2a total cell populations (similar results were obtained when comparing shRNA-Tsc2 + Cdkn2a spheres to control infected cells, data not shown) identified 584 genes that were >8-fold upregulated in spheres (Supplementary Data 1) . Interestingly, 93 of these genes overlapped with a set of 324 genes that are expressed at 10-fold or higher levels in S1 or S3 segments of Graph depicts mean ± s.d. Student's t test, n = 3. * * P < 0.01; * * * P < 0.001. d Positive immunofluorescence stainings of spheres using antibodies against NAPI2A, CATHEPSIN K, pan-CD133, MiTF, PMEL(HMB45) and MART-1. e Positive immunofluorescence and immunohistochemical stainings of AML-like allograft tumours using antibodies against NAPI2A, RCC, E-CADHERIN, CD10, CD133 and pan-CYTOKERATIN. Scale bars: 50 μm proximal tubules compared with distal tubules, loops of Henle and collecting ducts 30 (Fig. 3b) . In contrast, comparison with a cumulated list of 593 genes that are specifically upregulated either in distal tubules, loops of Henleor collecting ducts compared to proximal tubules 30 revealed an overlap of only 7 genes (Fig. 3b) . The upregulation of a subset of the identified proximal tubulespecific genes (Slc34a1, Slc13a3, Aqp1, Vil1, Cubn, Fmo1, Kap) in spheres compared with total shRNA-Tsc2/sh+Cdkn2a populations was confirmed by real time PCR analyses (Fig. 3c) . This result surprisingly demonstrates that spheres exhibit a stronger renal proximal tubule epithelial gene expression signature than cultured primary renal epithelial cells. Further supporting the epithelial nature of the spheres, Hnf4a was upregulated~10,000 fold in spheres (Fig. 3c ). Hnf4a encodes a transcription factor that (Fig. 3c ). These proximal tubule and transcription factor gene signatures were also present in the four clonal sphere lines and in AML allograft tumours (Fig. 3c) , suggesting that the engineered tumours display at least some of the characteristic gene expression profile of the proximal tubule epithelial cell, arguing that proximal tubular epithelial cells are the origin of these engineered tumours. Further supporting this notion, some cells in spheres expressed NAPI2A or stained positively for pan-CD133 (not the glycosylation-specific 'stem cell marker' antibody) (Fig. 3d) , which are expressed by normal renal proximal tubule epithelial cells. At the same time, shRNA-Tsc2 + Cdkn2a spheres also exhibited evidence of an AML or melanocyte-like phenotype as shown by immunoreactivity for the AML markers PMEL, CATHEPSIN K, MiTF and MART-1 (Fig. 3d) , expression of MiTF and CATHEPSIN K by western blotting ( Supplementary  Fig. 9a ) and upregulation of Tyrp1 gene expression in comparison to non-sphere populations or to Myc/Trp53 Δ/Δ sphere populations ( Supplementary Fig. 9b ). Spindle cells in allograft AML tumours (Fig. 3e ) also expressed the proximal tubule marker protein NAPI2A and epithelial structures in these tumours were positive for the epithelial markers E-CADHERIN and PAN-CYTOKERATIN and stained positively for pan-CD133, RCC and CD10 (Fig. 3e) , three markers of the renal proximal tubule epithelium. We conclude that AML-forming sphere cells can also differentiate into proximal tubule epithelial cells. Consistent with a renal epithelial phenotype, scattered cells in allograft tumours derived from total sphere populations or from sphere clonal cell lines expressed the transcription factor PAX8, which is normally expressed in epithelia of the renal and genital-urinary tract ( Supplementary Fig. 9c ). To gain further evidence for an epithelial origin of our engineered tumours we next genetically marked renal epithelial cells in vivo, labelling all nephron segments by doxycycline feeding of mice harbouring transgenes encoding Pax8 promoterregulated expression of rtTA, Tet-responsive Cre expression 33 and ROSA26-lox-STOP-lox-regulated tdTomato expression 34 (Pax8-rtTA;TRE-LC1;R26R-LSL-tdTomato) (Fig. 4a) . In total 85% of cells cultured from these kidneys were tdTomatopositive (Fig. 4b ) and when transformed with shRNA-Tsc2 + Cdkn2a lentiviruses 90% of the resulting spheres were tdTomatopositive (Fig. 4c) . These could be differentiated to form tdTomato-positive epithelial cells, adipocytes and glia (Fig. 4d) and expressed characteristic genes of differentiated lineages ( Supplementary Fig. 6b ). Negative staining controls are shown in Supplementary Fig. 10a-d . Allograft tumours derived from these cultures expressed tdTomato (Fig. 4e) and cells in tumour regions characterised by adipocyte, spindle cell and thick-walled blood vessel histology were labelled with tdTomato (Fig. 4f) . Similarly to the other tumours generated in this study, these allograft tumours stained positively for PMEL, CATHEPSIN K, PDGFRβ, SMA and VIMENTIN ( Supplementary Fig. 10e ), expressed PMEL by western blotting (Supplementary Fig. 10f ), and exhibited a similar frequency of PMEL expressing cells (Supplementary Fig. 10g) .
Cells isolated by collagenase digestion of resected tumours could be cultured as tdTomato-expressing spheres and sphereselected cells formed new tdTomato-positive allograft AML tumours (Fig. 4g) , establishing that these cells have tumourpropagating capacity, an expected feature of a neoplastic tumour stem cell. In contrast, in vivo lineage tracing of neural crestderived cells using Sox10-Cre;R26R-LSL-tdTomato mice labelled a set of non-tubular interstitial cells in the intact kidney (Fig. 4a ) that were present as rare clusters of tdTomato-labelled cells in our kidney cultures (Fig. 4b) . However, after infection with shRNATsc2 + Cdkn2a lentiviruses none of these cells contributed to spheres (Fig. 4c) or tumours (Supplementary Fig. 10h ), excluding that they are the cells of origin of our AML model. These studies collectively demonstrate that loss of function of Tsc2 and Cdkn2a in cultured proximal tubule epithelial cells converts them into an AML-forming neoplastic stem cell.
Guided by these results, we repeated a previously published experiment involving Pax8-Cre-driven inducible deletion of Tsc1 in adult renal epithelia using Pax8-rtTA;TRE-LC1;Tsc1 fl/fl mice 33 . As reported, within 2 months of homozygous deletion of Tsc1 in 6-8 week old mice, kidneys developed a severe polycystic phenotype with intermixed regions of adenoma-like epithelial proliferation but did not develop renal AMLs (Fig. 5a ). All cystic and adenoma-like regions stained strongly for phosphorylation of ribosomal protein S6 (Ser240/244), indicative of Tsc1 deletion (Fig. 5b) . Interestingly, however, immunohistochemical analyses revealed the presence of scattered PMEL positive cells that were present as single cells or clusters of 2-3 cells (on average 35 sites per mouse kidney section) within regions of solid or cystic epithelial proliferation (Fig. 5b) . PMEL staining was predominantly cytoplasmic (Fig. 5c) . PMEL positive cells were never observed in kidneys from wild type mice or Tsc1 heterozygous mutant mice (Pax8-rtTA;TRE-LC1;Tsc1 fl/+ ). Cysts and adenoma lesions also showed scattered cells expressing SMA, another marker of renal AMLs (Fig. 5b) . CATHEPSIN K staining was upregulated in all cells in cysts and adenomas (Fig. 5b) , and CATHEPSIN K protein expression was detected by western blotting in kidney lysates from homozygous, but not heterozygous Tsc1 mutant mice or wild type mice ( Supplementary  Fig. 3i ), suggesting that this increase is directly related to Tsc1 deletion and consistent with the fact that almost all cells in human renal AMLs express CATHEPSIN K 27 . Given that the strong hyperproliferative phenotype of Tsc1 homozygous deletion prevented aging experiments, we generated a cohort of 12 Pax8-rtTA;TRE-LC1;Tsc1 fl/+ heterozygous mutant mice and analysed them 1 year after inducing gene deletion in 6-8 week old mice. By histological sectioning of kidneys we identified 20 cysts (14 were lined by a single layer of epithelial cells, 6 cysts displayed atypical, multilayered morphology), 5 small tumours with epithelial morphology and 28 lesions comprising closely packed cells with low cytoplasmic volume, often occurring close to blood vessels ( Supplementary Fig. 11 ). These lesions exhibit a similar morphology to lesions that were identified upon Tsc1 deletion under a ubiquitious promoter and that were proposed to represent potential precursors of renal AMLs 22 . Consistent with this idea, the lesions in our mice harboured many cells that were positive for phosphorylation of ribosomal protein S6 (Ser240/ 244) and some cells that were positive for CATHEPSIN K, SMA, and more rarely for PMEL (Fig. 5b) . Thus, the epithelial-specific PAX8-Cre driver appears to recreate a similar phenotype to that previously described with the ubiquitous Cre driver. These observations provide in vivo evidence to show that loss of TSC function in renal epithelial cells can cause the formation of different lesions that contain cells that express several different molecular markers of renal AML, consistent with our ex vivo cell engineering studies.
Epithelial origin of human AMLs. We next sought to determine the relevance of these mouse-based findings to human renal AML. To overcome the senescence barrier associated with loss of TSC function in primary human cells, we employed RPTECs immortalised with SV40 large T Antigen and hTERT 35 and infected these cells with four independent shRNA-TSC2 lentiviruses, efficiently reducing TSC2 protein abundance (Supplementary Fig. 12a ) and inducing the formation of spheres in non-adherent culture conditions (Supplementary Fig. 12b ). These spheres could be differentiated into epithelial cells, adipocytes and glia in culture (Supplementary Fig. 12c ). Importantly, while immortalised RPTECs did not form sub-cutaneous tumours (n = 3 mice), two independent TSC2 hairpins (II and IV) caused the formation of xenograft tumours (n = 4 mice for each hairpin) that histologically resembled the characteristic spindle cell, vascular and adipocyte structures of human renal AMLs, and also displayed regions of epithelial structures (Supplementary Fig. 12d ). These tumours expressed the AML marker proteins HMB45, SMA, VIMENTIN, PDGFRβ and epithelial structures were positive for E-CADHERIN (Supplementary Fig. 12d ). In comparison to control cells, shTSC2 spheres exhibited increased mRNA expression of proximal tubule signature genes and transcription factor encoding genes that were upregulated in spheres engineered from mouse cells (Supplementary Fig. 12e ). Thus, cultured human renal proximal tubule epithelial cells are also converted to AML-forming cells by loss of function of TSC2 in cooperation with abrogation of cellular senescence.
Immunofluorescence staining of seven sporadic human AML tumours revealed that all tumours contained cells that express proteins that are expressed in proximal tubular epithelial cells in the kidney, namely NAPI2A, pan-CD133 and AQP1, but did not contain cells expressing THP, a marker of epithelial cells of the thick ascending limb of the loop of Henle (Fig. 6a) . Analyses of mRNA isolated from matched pairs of samples of normal kidney and AML tumour (n = 7 cases) from paraffin-embedded tissue revealed that all AMLs expressed similar or higher levels of proximal tubule marker genes (FMO1, CUBN, VIL1) and several transcription factor-encoding genes identified from our mouse studies (TAL1, HNF4A, TFEC) as normal kidney (Fig. 6b) . These findings corroborate our mouse tumour engineering findings and are consistent with the idea that human renal AMLs derive from renal epithelial cells.
We next obtained a set of isogenic renal AML cell lines to investigate whether these cells display similarities to our engineered models. TRI-102 cells are an immortalised (E6/E7 and hTERT) derivative 36 of a TSC2 null primary cell culture that was derived from a human renal AML 37 . TRI-103 is a derivative of TRI-102 into which TSC2 expression has been re-introduced 36 . Similarly to our engineered cells, TRI-102 but not TRI-103 cells formed spheres when grown in epithelial medium on nonadherent plates (Fig. 7a) . When grown as adherent cultures, both TRI-102 and TRI-103 expressed the mesenchymal marker VIMENTIN, as well as the epithelial marker E-CADHERIN (Fig. 7b) . TRI-102 cells also expressed the proximal tubule marker proteins CD133 and NAPI2A and the expression of these proteins was absent or reduced in TRI-103 cells (Fig. 7b) . TRI-102 cells when grown as adherent cells or as spheres expressed higher mRNA abundance than TRI-103 of the transcription factors and some of the proximal tubule genes that we identified in our engineered systems (Fig. 7c) . Finally, TRI-102 but not TRI- (Fig. 7d) . These findings establish that a cell line derived from a human renal AML have similar renal proximal tubule epithelial features and differentiation capacities to our engineered cellular systems.
Therapeutic studies using engineered AML models. In a recent phase 3 clinical trial of the mTORC1 inhibitor everolimus for large renal AMLs (>3 cm diameter) in TSC patients, 42% of the patients displayed a reduction in tumour volume of >50% within one year of treatment 20 and this therapy is now a recommended treatment for these patients. However, once everolimus therapy is discontinued, AML lesions typically resume growth 38, 39 . The cellular consequences of everolimus therapy in TSC patient renal AML tumours have not been able to be studied. To attempt to address this issue we utilised our engineered AML models. Everolimus caused a greater inhibition of proliferation of shRNATsc2/Cdkn2a Δ/Δ sphere-derived cells compared to control Cdkn2a Δ/Δ kidney cells when grown under adherent cell culture conditions (Fig. 8a) . Everolimus also decreased the number and size of spheres in non-adherent culture conditions (Fig. 8b-d ) without decreasing cellular viability (Fig. 8e) . Rather, everolimus decreased the proportion of S-phase cells and caused accumulation of cells in the G1 and G2/M cell cycle phases (Fig. 8f) . The addition of everolimus to cellular differentiation experiments did not alter the ability of shRNA-Tsc2/Cdkn2a Δ/Δ sphere cells to differentiate into different cellular lineages (Fig. 8g) . Everolimus treatment (10 mg/kg i.p.daily for 2 weeks) of mice harbouring shRNA-Tsc2/Cdkn2a Δ/Δ allograft tumours blocked tumour growth and tumours regressed after cessation of treatment but regrew after~3 months (Fig. 8h) . This behaviour mimics the clinical response to mTOR inhibitor therapy. Tumours harvested during everolimus treatment (Fig. 8i ) exhibited no apparent differences in histological appearance compared with untreated tumours (Fig. 8j) , nor in the abundance of PMEL immunoreactive cells (Fig. 8j, k) but contained fewer proliferating cells as assessed by BrdU labelling (Fig. 8l, m) . While everolimus caused a 3-fold increase in the number of cleaved caspase-3 positive cells, a marker of apoptosis (Fig. 8n) , it should be noted that the frequency of apoptotic cells was very low (<0.1% of cells) and is therefore unlikely to be the major contributor to the therapeutic effects of the drug. This observation is consistent with the cell culture data and demonstrates that mTORC1 inhibition predominantly induces cell cycle arrest of AML tumour cells, without any obvious effects on cellular differentiation, consistent with the observed absence of complete cures in renal AML patients.
Discussion
Biallelic loss-of-function mutations inTSC2 and more rarely in TSC1 appear to represent the key genetic driving events of renal AMLs 19 . We show that loss of function of TSC2 in genetic backgrounds that abrogate senescence and proliferation arrest is sufficient to convert mouse and human renal proximal tubular epithelial cells into neoplastic stem cells that give rise to allograft Adipocyte diff.
TRI-102 spheres
Relative mRNA abundance or xenograft tumours that reproduce many of the histological and molecular features of human renal AMLs, providing the first models of AML-like tumours. It should be noted that these tumours represent 'models' as the genetic backgrounds that we employed in this study to overcome cellular senescence induced mechanisms operating at the epigenetic, translational or protein levels may permit escape from senescence in human renal AML. In addition, our engineered, sub-cutaneously growing tumours do not fully reproduce all of the morphological features and growth patterns seen in human renal AMLs growing in the kidney. Nonetheless, our studies of our engineered model systems revealed some new features of human renal AMLs, supporting the relevance of our models. Our engineered cells exhibit a proximal tubule gene expression signature, express proximal tubule-specific proteins and display upregulation of several transcription factors that play diverse roles in development and cellular differentiation programmes. These gene expression signatures and protein expression pattern are also at least partly present in human renal AML tumours and in a cell line derived from a renal AML, arguing that this classic 'mesenchymal' tumour might have an epithelial origin. While unexpected, these findings are potentially consistent with a series of recent studies showing that renal epithelial cells can exhibit a range of different differentiation capacities. As part of the process of repair of injured tubules in response to kidney damage in vivo, renal proximal tubular epithelial cells adopt a mesenchymal appearance and express several molecular markers of mesenchymal cells and of stem cells, including the glycosylated form of CD133, CD24 and high aldehyde dehydrogenase activity [40] [41] [42] [43] . Isolation of these cells revealed that they grow as spheres and that they express a strong 'stemness' transcriptional profile 43 .
While not yet proven for cells isolated from the proximal tubule, isolation of a similarpopulation of CD133/ CD24-expressing parietal epithelial cells from the Bowman's capsule of the glomerulus revealed that these cells could be differentiated in culture into several types of renal epithelial cells, adipocytes, osteoblasts, endothelial cells and neuronal cells, suggestive of a multi-potent progenitor cell phenotype 44 . Thus, at least some and potentially all renal epithelial cells appear to exhibit a degree of cellular plasticity and can adopt progenitor or stem cell properties under certain circumstances 45 . Our observations that renal epithelium-specific heterozygous and homozygous deletion of Tsc1 in the mouse kidney causes the emergence of lesions in which at least some cells express molecular markers of renal AML is consistent with the notion that epithelial cells in vivo might have the capacity to become transformed to generate renal AMLs. Our genetically engineered tumour models provide the first experimental tools to further explore this idea and to define the molecular pathways that govern renal AML tumour biology, for example to assess the potential functions of upregulated transcription factors in causing cellular transformation and stemness. Our studies on the mechanistic basis of everolimus therapy provide proof-of-principle that these experimental models might also facilitate the future identification and pre-clinical validation of new therapeutic approaches for renal AMLs.
An interesting unanswered question is why mutation of TSC1 or TSC2 in humans predominantly causes the development of renal AMLs, renal cysts and more rarely of renal carcinomas, whereas Tsc1 or Tsc2 mutation in rats or mice causes renal cysts, adenomas and carcinomas, but does not lead to the formation of renal AMLs 21 . It is possible that the strong phenotypic effect of Tsc1 or Tsc2 deletion in causing epithelial hyperproliferation in the mouse kidney means that AMLs do not have the necessary time to develop in mouse models. Alternatively, we speculate that our cell culture setting in some way reproduces specific microenvironmental conditions, or niches, that are abundant in human kidneys but rare in mouse kidneys in vivo, and that these specific conditions are necessary for the formation of AMLs. One possibility could be the apparent enhanced rate of loss and replacement of renal epithelial cells in human nephrons compared to mouse nephrons that is believed to underlie the apparent 'spontaneous' epithelial to mesenchymal transition and acquisition of features of stemness in normal human kidneys but not in rodent kidneys 41 . Finally, it is possible that AML development requires additional, yet-to-be-identified genetic or epigenetic alterations that cooperate with loss of TSC function to promote the transition of an epithelial cell to an AML stem cell.
Renal AML belongs to a broader class of tumours termed PEComas that are named after the common presence of perivascular epithelioid cells (PEC). PEComas also include AMLs that form in other organs, lymphangioleiomyomatosis of the lung, clear-cell sugar tumour of the lung, clear-cell myomelanocytic tumour of the falciform ligament and other rare clear-cell tumours found at other anatomical sites 46 . PEComas represent a biological enigma as they share several cellular and molecular features and frequently involve TSC mutation, but the cell type(s) of origin of all of these tumours remains unknown; there is no known normal anatomical counterpart of the perivascular epithelioid tumour cell. By presenting evidence that suggests that the cell of origin of renal AMLs could be an epithelial cell, our studies suggest a new paradigm in the understanding of the biology of this disease and also suggest that epithelial cells in other organs might potentially represent the cells of origin of other types of PEComas. In view of our results, the classification of renal AML as a PEComamight be a misnomer and the current pathological terminology might need be reconsidered.
Methods
Mouse strains. The following mouse strains were utilised in this study: SCID/beige mutant mice (C.B-17/CrHsd-Prkdc scid Lyst bg-1 ) and C57BL/6J OlaHsd mice were from n Quantification of number of cells per ×40 microscopy field staining positively for cleaved caspase 3 in tumours from i. All graphs depict mean ± s.d. Student's t test, n = 3. * P < 0.05; * * P < 0.01; * * * P < 0.001
Harlan Laboratories. Cdkn2a fl/fl (FVB;129P2-Cdkn2a tm2Brn /Cnrm) 47 were from EMMA (EM:00407). Sox10-Cre mice have been previously described 48 . Tsc1 fl/fl (Tsc1 tm1Djk /J) 24 mice were from Jackson Laboratory (005680). Ai14 td-Tomato reporter mice (B6.Cg-Gt(ROSA)26Sor tm14(CAG-tdTomato)Hze /J) 34 were from Jackson Laboratory (007914). Pax8-rtTA;TRE-LC1 33 mice were obtained from Prof. Carsten Wagner, University of Zurich and were intercrossed with Tsc1 fl/fl mice. Approximately 6-8 week old were exposed to doxyxycline (5 mg/ml) in drinking water supplemented with 5% sucrose for 5 days. Animals were subsequently kept on normal drinking water for 2 months. All mouse experiments were approved by the Veterinary Office of the Canton of Zurich under the licence 06/2013. No statistical method was used to predetermine sample size. The experiments were not randomised and the investigator was not blinded to the genotype of mice.
Allograft and xenograft experiments. For allograft and xenograft experiments, SCID/beige mice were anesthetised and injected subcutaneously with 5 × 10 6 cells suspended in 50% Matrigel (BD, no.354230). Tumour growth was monitored throughout the experiment and tumour size measured with calipers every 3 days. Everolimus treatment (10 mg/kg i.p.) of mice harbouring AML allograft tumours was performed daily for 2 weeks.
Cell culture. Primary MEFs were isolated from E13.5 embryos from WT (C57BL/ 6) or Cdkn2a fl/fl strains, cultured in DMEM plus 10% fetal bovine serum (FBS) in cell-culture incubators supplemented with 5% CO 2 and maintained at 5% O 2 . Murine primary kidney cells were isolated and cultured in complete K-1 culture medium (DMEM-F12 medium (D6421, Sigma) supplemented with 0.5% FBS, 25 mM Glutamine, 5 mg/ml insulin, 1.25 ng/ml prostagladin E1, 34 pg/ml 3,3,5 Triiodothyronine, 5 mg/ml human Apo-transferrin, 1.75 ng/ml sodium selenite, 20 ng/ml Hydrocortisone and 25 ng/ml murine epidermal growth factor) as described 49 . For non-adherent cultures to induce sphere formation, kidney cells (2 × 10 3 ) were plated in ultra-low attachment culture plates (Corning, 3471) and incubated in complete K-1 culture medium. The spheroids appeared after~7-10 days in culture. Spheres were dissociated into single cells using Accutase (Gibco, A-11105-01) for replating or for other assays. Human Renal Proximal Tubular Epithelial Cells (RPTEC) TH1 cell line is derived from primary human renal proximal tubule epithelial cells immortalised by two lentiviral vectors carrying the human telomerase (hTERT) and the SV40 T antigen 35 . These cells, as well as B16F1 cells, were cultured in DMEM plus 10% FBS in cell culture incubators at 37°C , 5% CO 2 and 5% O 2 . The TRI-102 and TRI-103 cell lines were kindly provided by Elizabeth Henske (Brigham and Women's Hospital, Boston) and cultured in K1 medium in cell culture incubators at 37°C, 5% CO 2 and 5% O 2 . RPTEC TH1, TRI-102 and TRI-103 cells tested negatively for mycoplasma and were validated based on resistance to selection markers (Neo or Zeo) as well as by western blotting for exogenously expressed proteins (SV40 Large T-antigen).
Adipocyte differentiation: Cells obtained from spheres were cultured in DMEM high Glucose, 10% FBS, supplemented with 0.5 mM IBMX, 0.25 μM Dexamethasone, 1 μg/mL Insulin and 2 μM Rosiglitarone. 48 h later medium was changed to DMEM high Glucose, 10% FBS, supplemented with 1 μg/mL Insulin for 48 h. After this treatment, cells were cultured in DMEM high Glucose, 10% FBS without supplements for 7 days.
Neuralcrest differentiation: Cells obtained from spheres were cultured in DMEM-F12 medium, 5% FBS, supplemented with 160 nM TPA (12-Otetradecanoyl phorbol-13-acetate), 50 ng/mL mSCF (Stem cell factor, mouse, recombinant), 100 nM ET-3 (Endothelin 3, human), 25 ng/mL bFGF (Fibroblast growth factor-basic, human), 100 ng/mL α-MSH (α-Melanocyte stimulating hormone) and 1 nM Dexamethasone for 10 days.
Osteoblast differentiation: Cells obtained from spheres were cultured in DMEM high Glucose, 10% FBS, supplemented with 0.2 mM ascorbic acid, 0.25 μM Dexamethasone and 10 mM β-Glycerol phosphate for 14 days.
Epithelial differentiation: Cells obtained from spheres were cultured in complete K-1 media for 10 days. Viral infections. MEFs and primary kidney cells were infected with adenoviruses expressing GFP (Vector Biolabs, 1060) or Cre-GFP (Vector Biolabs, 1700), lentiviruses (LKO.1) expressing non-silencing hairpin (Addgene, 10879) or shRNA against Tsc1 (Sigma, TRCN0000238187) or shRNA against Tsc2 (Sigma, TRCN0000306244). For lentiviral-mediated knockdown of Cdkn2a and Tsc2, we generated a MuLEvector 50 containing U6 promoter-driven expression of shRNA against Cdkn2a, 7SK promoter-driven expression of shRNA against Tsc2 and PGK promoter-driven expression of puromycin resistance. Human RPTECs were infected with lentiviruses expressing non-silencing hairpin (Addgene, 1864) or four different shRNAs against TSC2 (Sigma, TRCN0000295896, TRCN000010455, TRCN000010454 and TRCN000040182). All cells were incubated overnight in virus-containing medium in the presence of 4 μg/ml polybrene (Sigma-Aldrich, no. H9268). Drug selection was performed 48 h after transduction using 4 μg/ml of puromycin. Cells were isolated from dissected tumours by digestion for 1 h at 37°C with 1 mg/ml collagenase type II (Gibco, Life Technologies), washed twice with PBS, and cultured in DMEM plus 10% FBS. Cellular assays. Cellular senescence was evaluated using the Senescence kit (Calbiochem QIA 117). For proliferation assays, cells were seeded at 2 × 10 5 cells per 6 cm dish in triplicate dishes and counted after 3 days before reseeding at the same density for the next passage. All proliferation assays shown are representative of at least three independent experiments. Cell viability within the spheres treated with and without everolimus was measured with a Trypan Blue viability assay.
Drug Assays. Transformed primary kidney cells were seeded at a density of 2 × 10 3 cells per well on a 96 well plate. After attachment of the cells, everolimus was individually added at different concentrations and medium changed every two days to ensure addition of new drug. Cells were fixed after 7 days in 5% w/v trichloracetic acid and stained in 0.057% w/v Sulforhodamine B (SRB) solution and air-dried. SRB was solubilized by incubation in the 10 mM Tris base solution (pH 10.5) and OD was measured at 540 nm in a micro-plate reader.shRNA-Tsc2/ Cdkn2a Δ/Δ spheres were cultured in the presence or absence of everolimus (1.6 nM) for 48 h.
Electron microscopy. Tissue culture samples were fixed in 2.5% buffered glutaraldehyde overnight, postfixed in 1% osmium tetroxide for 2 h, dehydrated in graded alcohols, incubated in pure propylenoxide and then propylenoxide-Epon mix and then embedded in Epon. The sections were cut with diamond knives on an ultramicrotome (Ultracut E, Reichert Jung, 90 nm sections), stained with uranyl acetate and lead citrate, and examined using a Hitachi TEM type H-7650 electron microscope.
Statistics. Statistical significance was determined by two-tailed Student's test, with a P value <0.05 considered to be statistically significant. 
